Niraparib NEW
| Price | $55 | $80 | $113 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-01 |
Product Details
| Product Name: Niraparib | CAS No.: 1038915-60-4 |
| Purity: 99.91% | Supply Ability: 10g |
| Release date: 2024/11/01 |
Product Introduction
Bioactivity
| 名稱 | Niraparib |
| 描述 | Niraparib (MK-4827) is a PARP inhibitor that selectively targets PARP1 and PARP2 (IC50=3.8/2.1 nM), exhibiting antitumor activity, inhibiting DNA damage repair, and inducing apoptosis. |
| 細(xì)胞實(shí)驗(yàn) | Proliferation assays were conducted in 96-well black viewplates, and 300 cells/well (250 cell/well for BRCA-1 wt) in culture medium, 190 μL/well (DMEM containing 10% FCS, 0.1 mg/mL penicillin-streptomycin, and 2 mM L-glutamine), were plated and incubated for 4 h at 37℃ under 5% CO2 atmosphere. Inhibitors were then added with serial dilutions, 10 μL/well to obtain the desired final compound concentration in 0.5% DMSO. The cells were then incubated for 7 days at 37℃ in 5% CO2 after which time viability was assessed. Briefly, with CellTiter-Blue solution prediluted 1:10 in medium, 100 μL/well was added and the cells left for 45 min at 37℃ under 5% CO2 and then a further 15 min at room temperature in the dark. The number of living cells was determined by reading the plate at fluorimeter, excitation at 550 nm and emission at 590 nm. Cell growth was expressed as the percentage growth with respect to vehicle treated cells. The concentration required to inhibit cell growth by 50% (CC50) was determined.(Only for Reference) |
| 激酶實(shí)驗(yàn) | Enzyme assay is conducted in buffer containing 25 mM Tris, pH 8.0, 1 mM DTT, 1 mM spermine, 50 mM KCl, 0.01% Nonidet P-40, and 1 mM MgCl2. PARP reaction contains 0.1 μCi [3H]NAD+ (200?000 DPM), 1.5 μM NAD+, 150 nM biotinylated NAD+, 1 μg/mL activated calf thymus, and 1?5 nM PARP-1. Autoreactions utilizing SPA bead-based detection are carried out in 50 μL volumes in white 96-well plates. Compounds (e.g., MK-4827) are prepared in 11-point serial dilution in 96-well plate, 5 μL/well in 5% DMSO/Water (10× concentrated). Reactions are initiated by adding first 35 μL of PARP-1 enzyme in buffer and incubating for 5 min at room temperature and then 10 μL of NAD+ and DNA substrate mixture. After 3 h at room temperature, these reactions are terminated by the addition of 50 μL of streptavidin-SPA beads (2.5 mg/mL in 200 mM EDTA, pH 8). After 5 min, they are counted using a TopCount microplate scintillation counter. IC50 data is determined from inhibition curves at various substrate concentrations[1]. |
| 體外活性 | METHODS: The PDAC cell lines MIA-PaCa-2, PANC-1, Capan-1 and the OvCa cell lines OVCAR8, PEO1 were treated with Niraparib (0.1-200 μM) for 48 h, and the cells were assayed for viability using the CellTiter-Glo Luminescent Cell Viability Assay. RESULTS: The IC50 of Niraparib on MIA-PaCa-2, PANC-1, Capan-1, OVCAR8, and PEO1 cells were 26 μm, 50 μm, 15 μM, 20 μM, and 28 μM, respectively.[1] [2]. METHODS: Ovarian cancer cells SKOV3 and UWB1.289 were treated with Niraparib (0.5-15 μM) for 48 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Niraparib upregulated the expression of PD-L1 in SKOV3 and UWB1.289 cells. [2] |
| 體內(nèi)活性 | METHODS: To detect anti-tumor activity in vivo, Niraparib (25 mg/kg, administered orally four times per week) and PD-L1 (10 mg/kg, administered intraperitoneally twice per week) were administered to C57BL/6 mice bearing ovarian cancer tumor ID8 for eight weeks. RESULTS: Niraparib upregulated PD-L1 expression in ovarian tumors in vivo and synergized with PD-L1 blockade. [2] METHODS: To detect anti-tumor activity in vivo, Niraparib (50 mg/kg, 0.5% methylcellulose) was administered by gavage to C57BL/6 mice bearing intracranial human-derived TNBC cell lines SUM149, MDA-MB-231Br, or MDA-MB-436 once daily for two weeks. RESULTS: In the BRCA mutant MDA-MB-436 model, Niraparib increased median survival and decreased tumor load. However, it did not increase in the BRCA mutant SUM149 or BRCA wild-type MDA-MB-231Br models, despite high concentrations in intracranial tumors. [3] |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : 60 mg/mL (187.3 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 6 mg/mL (18.73 mM), Working solution is recommended to be prepared and used immediately. DMSO : 16.67 mg/mL (52.02 mM), Sonication is recommended. |
| 關(guān)鍵字 | breast | DNA | damage | inhibit | cancer | anti-tumor | poly ADP ribose polymerase | bioavailable | Niraparib | PARP | orally | Apoptosis | Inhibitor | lung | ovarian | MK4827 | MK 4827 |
| 相關(guān)產(chǎn)品 | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin |
| 相關(guān)庫 | 高選擇性抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌臨床化合物庫 | 藥物功能重定位化合物庫 | 抑制劑庫 | FDA 上市藥物庫 | 抗癌上市藥物庫 | 已知活性化合物庫 | 抗癌藥物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1KG |
VIP3Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-10-25 | |
| $0.00/10g |
VIP2Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-11 | |
| $0.00/10mg |
VIP1Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-05-07 | |
| $8.00/1kg |
VIP1Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-08 | |
| $0.00/1kg |
VIP1Y
|
Nanjing Fred Technology Co., Ltd
|
2023-12-25 | |
| $100.00/10kgkg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-07 | |
| $0.00/1kg |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-06-30 | |
| $100.00/25kg |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2022-07-04 | |
| $100.00/1g |
Qiuxian Baitai New Material Co., LTD
|
2021-11-05 | ||
| $0.00/25KG |
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-14 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY